tradingkey.logo

EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment

ReutersJun 20, 2025 10:17 AM

- EMA's CHMP:

  • POSITIVE OPINION WAS ADOPTED FOR OGSIVEO, FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMOURS

  • NINTEDANIB VIATRIS GOT POSITIVE OPINION FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS, CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES

  • RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR REZDIFFRA, FOR TREATMENT OF ADULTS WITH NONCIRRHOTIC MASH

  • RECOMMENDED GRANTING MARKETING AUTHORISATION FOR AUSTEDO FOR TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE TARDIVE DYSKINESIA

  • POSITIVE OPINION FOR TENOFOVIR ALAFENAMIDE FOR TREATMENT OF ADULTS AND ADOLESCENTS INFECTED WITH HIV-1

  • STARTED RE-EXAMINATION OF ITS MARCH 2025 RECOMMENDATION NOT TO GRANT A MARKETING AUTHORISATION FOR KISUNLA ON JUNE 2

Source text: [ID:]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI